Just a month after we upgraded Acrux, the Financial Review has published the case for selling. That’s despite the most recent research finding testosterone replacement therapy (TRT) is safer than earlier studies suggested.
Life science stocks are not the most preferred of plays in an uncertain economic environment but as with all sectors of the market it is necessary to sift through the sector to find those companies that have the potential to deliver solid investment returns even in the currently unfavourable market conditions.
Acrux has created and patented an innovative Metered Dose Transdermal System, the broker reports, which delivers existing drugs through the skin. Various conditions can thus be treated with a spray-on delivery.